Opinion|Videos|April 15, 2026
Implications of the FDA Approval of Subcutaneous Amivantamab in EGFR+ NSCLC
Author(s)Christine M. Lovly, MD, PhD, Matthew Lee, MD
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss how the FDA approval of a subcutaneous formulation of amivantamab will affect clinical practice
Advertisement
Episodes in this series
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss the clinical implications of the FDA approval of amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; subcutaneous amivantamab) in EGFR-mutated non–small cell lung cancer. Lovly highlights how this formulation may improve patient convenience and reduce administration-related burden compared with intravenous delivery. Lee notes that these changes could influence treatment selection by improving the overall risk–benefit profile and patient experience.
Advertisement
Related to this article
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.
The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Advertisement
Advertisement
Trending on OncLive
1
RP1 Plus Nivolumab Preserves Quality-Adjusted Survival in Advanced Melanoma After Anti–PD-1 Therapy
2
Afami-Cel Outcomes Are Tied to MAGE-A4 Expression, Tumor Burden in Synovial Sarcoma
3
STX-001 Produces Durable Systemic Responses in PD-1–Resistant Melanoma
4
VET3-TGI Generates Responses in Checkpoint Inhibitor–Refractory Cutaneous Cancers
5